

HAPA STATUS UPDATE

06/23



Dear Investors, we appreciate your continued support and interest in HAPA pharm. We are pleased to share with you the latest developments of our company and our future plans.



CURRENT DEVELOPMENTS AT HAPA

EXPOPHARM: HAPA has an impressive booth at Expopharm, Europe's largest trade fair for the pharmaceutical industry. There we showcased our expanded range of varieties and introduce new formulations and innovative dosage forms. The event provides an excellent platform to strengthen our position in the market and showcase our latest offerings.

ADVISORY BOARD: We are pleased to announce the formation of our Advisory Board, comprised of industry experts and opinion leaders.

This advisory board will provide valuable insight and support to inform our strategic decision-making processes and ensure HAPA remains at the forefront of the cannabis industry.



<https://hapa.link/j4>

HAPA 2.0: We are working on the launch of a range of prescription medicines in various dosage forms. These products will be based on extensive research and development and will offer our customers a wider range of options.

IPO: Exciting times are ahead for HAPA as we are currently in the midst of our pre-IPO phase. Our strategy for growth includes taking the company public, with the Initial Public Offering (IPO) being planned for the third quarter of 2024. This milestone

represents our commitment to expanding our reach and enhancing shareholder value.

METASTUDY SUMMARY ON GINGKO AND CANNABIS BPSD: We have produced a poster on the links between ginkgo and cannabis in the context of the treatment of BPSD (Behavioral and Psychological Symptoms of Dementia). These research findings are promising and could lead to new therapeutic approaches.



<https://hapa.link/j5>

DEVELOPMENTS IN NORTHERN MACEDONIA: In Northern Macedonia, we are expanding and improving our existing production facilities. We have an experienced new grower, Michael Standor, on our team to help us further expand our production capacity.

DEVELOPMENTS IN GERMANY: We recorded a significant increase in sales in the pharmacy business. In addition, we have significantly improved our customer acquisition, particularly in the pharmacy sector. We are also in advanced discussions about further expansion into other European countries. The legalization of medical cannabis and the strengthening of the medical sector are important focal points of our strategy.

We are confident that these developments and plans will help to further increase value for our shareholders. If you have any questions, please contact Michael Sprenger (ms@hapa-pharm.com), our Head of Investor Relations.

Kind Regards

A handwritten signature in green ink, appearing to read 'Ricardo Pendon'.

Ricardo Pendon

HAPA pharm GmbH | Phoenixseestr. 4 | 44263 Dortmund
Amtsgericht Dortmund | HRB 29290 | VAT ID: DE266562742 | Director & CEO: Ricardo Pendon Victorio
info@hapa-pharm.com | www.hapa-pharm.com

HAPA PHARM PRESENTS NEW ADVISORY BOARD MEMBERS



After thorough selection and planning, HAPA pharm is proud to announce the composition of its Advisory Board. The board consists of recognised experts from various fields who have joined at different times:



PROF. DR. ASCHER SHMULEWITZ M.D. joined in January 2023. He has over 30 years of experience as a life science scientist and more than 25 years of experience leading and expanding biopharma companies in the USA, Europe, and Israel. Particularly noteworthy is his long-standing collaboration with the late Raphael Mechoulam, a pioneer of cannabis research.



PROF. DR. MARKUS VEIT PH.D., who also joined in January 2023, is a member of the German Pharmacopoeia Expert Committee at BfArM and was involved more than 200 approvals of medicines in Europe and the US in his over 25-year career. His expertise lies in the areas of pharmaceutical development, testing, and regulatory affairs. His key expertise covers any aspects related to herbal medicinal products.



DR. CHRISTIAN RYBAK has been part of the board since November 2022. He is a renowned attorney and partner at Ehlers & Partner. With his international reputation in strategic and health policy consulting, particularly in Germany, he brings a wide range of expertise to the team. Additionally, he is a lecturer at the University of Bayreuth (health law) and the University of Münster (School of Tax and Business Law).



HÉCTOR JAUSÀS also a member of the board since November 2022, has over 25 years of experience in the pharmaceutical sector as a lawyer, partner, and head of Fieldfisher's Life Sciences Department. He is a member and former partner of Conférence Bleue and a corresponding member of the Royal Academy of Pharmacy of Catalonia.

Ricardo Pendon, CEO of HAPA pharm, emphasises the role of the Advisory Board in the future development of the company: *„With a clear focus on product development and patient welfare, the Advisory Board is committed to constantly improving the quality and efficiency of HAPA pharm's services. We will present first results and new products at the end of September at Expopharm, one of Europe's largest pharmaceutical trade fairs.“*

The entire team is looking forward to the collaboration and expects outstanding results due to the high level of expertise. As we continue to expand our board, we anticipate welcoming another prominent member to our team in the coming days. So stay tuned.